Avillion is a drug development company with an innovative business model for the clinical development and approval of late stage pharmaceutical products.
Top Service Category
- (09.Sep.2021) Fixed-Dose Combination of Albuterol and Budesonide (PT027) Demonstrated Significant Benefits for Asthma Patients in MANDALA and DENALI Phase III Trials
- (06.May.2021) MoonLake Immunotherapeutics Announces Publication in the Lancet of Impressive Phase 2b Data Showing Its Tri-Specific Nanobody Sonelokimab Totally Clears Skin in Almost 6 Out of 10 Patients With Moderate to Severe Psoriasis
- (23.Apr.2021) Avillion's Positive Phase 2 Trial of Tri-Specific Nanobody Sonelokimab (M1095) in Chronic Psoriasis Published in the Lancet
- (29.Oct.2020) Positive Results From Avillion's Phase 2 Trial of Sonelokinab (M1095) in Chronic Psoriasis to Be Presented Today in Late-Breaking News Session at EADV 2020 Virtual